التفاصيل البيبلوغرافية
| العنوان: |
Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. |
| المؤلفون: |
Peng-Yu Yang, Huafei Zou, Chao, Elizabeth, Sherwood, Lance, Nunez, Vanessa, Keeney, Michael, Ghartey-Tagoe, Esi, Zhongli Ding, Quirino, Herlinda, Xiaozhou Luo, Welzel, Gus, Guohua Chen, Singh, Parminder, Woods, Ashley K., Schultz, Peter G., Weijun Shen |
| المصدر: |
Proceedings of the National Academy of Sciences of the United States of America; 4/12/2016, Vol. 113 Issue 15, p4140-4145, 6p |
| مصطلحات موضوعية: |
EXENDINS, TRANSDERMAL medication, GLUCAGON-like peptide-1 agonists, GLUCAGON-like peptide-1 receptor, PHARMACOKINETICS, PHARMACODYNAMICS |
| مستخلص: |
Antidiabetic treatments aiming to reduce body weight are currently gaining increased interest. Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice daily via s.c. injection, improves glycemic control, often with associated weight reduction. To further improve the therapeutic efficacy of exendin-4, we have developed a novel peptide engineering strategy that incorporates a serum protein binding motif onto a covalent side-chain staple and applied to the peptide to enhance its helicity and, as a consequence, its potency and serum half-life. We demonstrated that one of the resulting peptides, E6, has significantly improved half-life and glucose tolerance in an oral glucose tolerance test in rodents. Chronic treatment of E6 significantly decreased body weight and fasting blood glucose, improved lipid metabolism, and also reduced hepatic steatosis in diet-induced obese mice. Moreover, the high potency of E6 allowed us to administer this peptide using a dissolvable microstructure-based transdermal delivery system. Pharmacokinetic and pharmacodynamic studies in guinea pigs showed that a single 5-min application of a microstructure system containing E6 significantly improved glucose tolerance for 96 h. This delivery strategy may offer an effective and patient-friendly alternative to currently marketed GLP-1 injectables and can likely be extended to other peptide hormones. [ABSTRACT FROM AUTHOR] |
|
Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder